According to Schoot et al., MTC patients receiving dendritic cell vaccination therapy revealed a calcitonin- and CEA-specific immunoreactivity of T-cell response, leading to tumor regression (57). This evidence concerns the gene CALCA and medullary thyroid gland carcinoma.